Abstract: The primary purpose is to do cancer risk assessment of toxaphene by using four steps of risk assessment proposed by the United States National Academy of Sciences/National Research Council (NAS/NRC). Four steps of risk assessment including hazard identification, dose-response relationship, exposure assessment, and risk characterization were used to evaluate cancer risk of toxaphene. Toxaphene was the most heavily used insecticide in many parts of the world before it was banned in 1982. It increased incidence of neoplasms of liver and uterus in mice and increased incidence of neoplasms of endocrine organs, thyroid, pituitary, adrenal, mammary glands, and reproductive systems in rats. From mice's and rats' study, slope factor for toxaphene is 0.8557 (mg/ kg/day) -1
Introduction
Toxaphene is a complex mixture of polychlorinated monoterpenes with a broad spectrum of pesticidal activity. Before its ban in 1982, it was the most heavily used insecticide in the United States and many parts of the world. When dichlorodiphenyltrichloroethane (DDT) was banned in the early 1970s, toxaphene replaced DDT as a major agricultural insecticide. Cumulative world use of toxaphene during the period 1946 to 1974 exceeded 409,000 metric tons. While its primary use has been on cotton, it has also been sprayed extensively on soybeans and peanuts, and has been used as a cattle dip. Toxaphene was also used by fisheries managers as a fish poison to rid lakes of undesirable fish. It was approved as a herbicide against sicklepod weed in 1980, and its use on soybeans, both as an insecticide and herbicide, outstripped cotton applications. Most registrations for toxaphene were canceled by the U.S. Environmental Protection Agency (EPA) in November 1982 because of its acutely and chronically toxic to aquatic life and its carcinogenic risk to human 1) . However, toxaphene can persist in the environment for a long period of time. Toxaphene have been detected in several environmental media and its residues have also been found among several kinds of animals. When toxaphene was being manufactured and used as an insecticide, occupational exposure to toxaphene, particularly via the dermal and inhalation routes, may have been significant. Any farmers, farm workers, or pesticide applicators who formerly used the mixture to control insects on livestock and crops may have been exposed to relatively high concentrations via these exposure routes 2) . The primary purpose of this paper is to do cancer risk assessment of toxaphene.
Methods
The four steps of risk assessment proposed by the National Academy of Sciences/National Research Council (NAS/ NRC) were followed. Hazard identification was done from review articles regarding properties and carcinogenicity of toxaphene. Using data of carcinogenic studies of toxaphene performed dose-response assessment step. Exposure assessment was done by reviewing level of toxaphene monitored in the environment. Integrating data from all three steps above performed the last step, risk characterization, to get carcinogenic risk of toxaphene.
Results

I. Hazard Identification Pharmacokinetics
Toxaphene is a complex mixture of many structurally related chlorinated terpenes with an average empirical formula of C 10 H 10 Cl 8 1) . No studies were located regarding the oral absorption of toxaphene in humans. However, there is strong evidence to suggest that gastrointestinal absorption occurs in humans. Deaths and poisonings resulting from the accidental ingestion of toxaphene-contaminated food have been reported. The presence of toxaphene residues in the fat of rats, mice, guinea pigs, hamsters, rabbits, monkeys and chickens following ingestion indicates that absorption occurred. The identification of toxaphene in the milk of cows following ingestion is also evidence of its absorption. The data suggest that toxaphene would be absorbed by humans following the consumption of drinking water or food contaminated with the chemical. Its absorption appears to be extensive and is enhanced when it is dissolved in a vehicle that is readily absorbed. The bioavailability of toxaphene is increased when it is administered in or with vegetable oils like corn oil or peanut oil, and the toxicity of toxaphene is potentiated. No studies were located in humans or animals regarding the dermal absorption of toxaphene. However, the detection of high toxaphene level in cow's milk (21-45 ppm) after dipping the cattle in a toxaphene solution indicates that toxaphene was absorbed following dermal exposure. Dermal absorption in animals was extensive following exposure to very high levels. Though the extent of absorption was not measured, the evidence suggests that absorption in humans may also substantial following dermal exposure 2) . A result of tissue sample analysis following the oral administration of radiolabeled toxaphene to rats showed that fat is the principal storage tissue. Other evidence in animals indicates that muscle may also be a storage depot for toxaphene. Toxaphene and its metabolites have also been detected in the liver, kidney, bone, brain, heart, lung, spleen and testes of rats 14 d after the oral administration of 14 Ctoxaphene. In investigations of effects on the adrenal gland, oral administration of 14 C-toxaphene to rats resulted in its distribution to the adrenal cortex. Radioactivity was primarily localized in the zona fasciculata. Oral administration of 14 C-toxaphene to pregnant rats resulted in the overall amount of placental transfer much less than 1% of the dose 2) . Toxaphene is rapidly and extensively degraded in mammals following oral administration. This was clearly evident after analyzing solvent extracts from urine, feces, and tissues. In vivo and in vitro studies indicated that the principal metabolic pathways involved dechlorination, dehydrodechlorination, and oxidation. Conjugation is also likely, but it is not a major route of metabolism 2) . It is evident from distribution studies that toxaphene and its metabolites are not persistent in tissues. Metabolism studies indicated that it is rapidly and extensively biodegraded. Consequently, the rate of toxaphene elimination is very high. The average percentage of an orally administered 20 mg/kg 36 Cl-toxaphene dose excreted over 9 d (approximate half-life of excretion) was 52.6%. Approximately 30% of this amount was excreted in the urine and 70% was excreted in the feces. Fecal excretion reached a plateau 2-3 d after administration. The cumulative urinary excretion steadily increased over the 9 d. Much of the activity in the urine and feces was attributable to 36 Cl-chloride ion. Therefore, dechlorination is a principal metabolic route of toxaphene that facilitates its elimination. Information regarding the excretion of toxaphene in animals following dermal absorption is limited. Evidence for the excretion of toxaphene in milk is evident based on a study conducted with cows. The absorption, distribution, and excretion of toxaphene were evident from these studies, but insufficient information regarding the dose of toxaphene precludes any estimation of the extent and rate of excretion 2) .
Carcinogenicity
No epidemiological studies relating specifically to the carcinogenicity of toxaphene were available. An increased incidence of lung cancer (10 observed versus 0.54 expected) were reported among 285 workers who applied various pesticides in agricultural settings. Some of these workers were exposed to toxaphene but they may have been exposed to compounds other than toxaphene or in addition to toxaphene. No evaluation specific for toxaphene could be made on the basis of this study. In a survey of 199 employees who worked or had worked with toxaphene between 1949 and 1977, with exposure ranging from 6 months to 26 yr (mean 5.23 yr), 20 employees died, 1 with cancer of colon; none of these deaths appeared to be related to exposure to toxaphene 3) .
Reuber, who reviewed carcinogenicity of toxaphene, showed that it is highly carcinogenic in rats and mice, inducing malignant neoplasms of the liver 4) . Increased neoplasms at all sites, as well as malignant neoplasms, were recorded in male and female rats ingesting toxaphene. Sarcoma were found more often in male rats, and carcinomas in female rats. Induced neoplasms of the endocrine organs were also reported in toxaphene-treated male and female rats, as well as an increased incidence of neoplasms of the reproductive system in female rats. Toxaphene-induced malignant neoplasms of the liver were reported in male and female mice. An increased incidence of malignant neoplasms at all sites was also reported. In addition to hepatic neoplasms, also reported were male mice with leukemia or lymphosarcoma and females with sarcomas of the uterus.
From the National Cancer Institute (NCI)'s mouse study, groups of 50 male and 50 female 5-week-old B 6 C 3 F 1 mice were fed technical-grade toxaphene in the diet. An increased incidence of hepatocellular carcinomas was found in treated mice 3) . Also, the incidence of stromal cell carcinomas of the uterus was slightly increased in female mice ingesting the high dose of toxaphene. From the NCI's rat study, groups of 50 male and 50 female 5-week-old Osborne-Mendel rats were fed diets containing technical-grade toxaphene. There were increases in benign and malignant neoplasms at all sites in males ingesting the low dose or high dose of toxaphene compared with the pooled controls. The increase in malignant neoplasms was in both carcinomas and sarcomas. There were marked increases in benign and malignant neoplasms at all sites in female rats ingesting the low dose or the high dose of toxaphene compared with the pooled controls. Carcinomas were noticeably increased in female rats given the low dose or the high dose compared with controls. There were increases in benign and malignant neoplasms of the endocrine organs in toxaphene-treated male rats. The predominant changes were the increase in carcinomas and decrease in adenomas of the endocrine organs in the treated rats. There were increases in carcinomas of the endocrine organs in toxaphene-treated female rats. Adenomas and carcinomas of the thyroid gland were present in male rats on the high dose, compared with the pooled controls. There were also increases in adenomas and carcinomas of the thyroid gland in the high-dose female rats. Carcinomas of the pituitary were increased, as were adenomas and carcinomas of the pituitary, in male rats ingesting the low dose of toxaphene, compared with pooled controls. There were increased carcinomas of the pituitary, in female rats ingesting the low dose of toxaphene, compared with pooled controls. Benign neoplasms, carcinomas, and total neoplasms were increased in the adrenal glands of female rats ingesting the low dose and the high dose of toxaphene. There was an increase in adenomas in the high-dose female rats. Total neoplasms were increased in the high-dose male rats, compared with the pooled controls. Benign and malignant neoplasms of the reproductive system were increased in female rats. The increases were predominantly in malignant neoplasms. Benign and malignant tumors of the mammary gland were increased in male rats ingesting the low and high doses of toxaphene. The increases were mainly in malignant neoplasms 4) .
II. Dose-response Assessment
In this study, quantitative risk assessment was based on only carcinogenic effects of toxaphene. Because of lacking epidemiological study for carcinogenic effect of toxaphene, only animal data were used for quantitative risk assessment. Animal data that are used in assessment are from the NCI's study of mouse and rat that are explained briefly in hazard identification section (Tables 1 and 2 ).
Calculation for slope factor
Using data from NCI mouse and rat studies above to derive slope factor for all cancer sites and specific cancer of male, female mice and rats. The linearized model was chosen because it is currently used by the EPA to protect human health by using 95% upper bound of slope factor for estimation of cancer risk. By assuming that these data are linear, equation for deriving slope factor and 95% confidence interval (CI) of slope factor are The following tables show the value of slope factors for cancer from mouse (Table 3) , and rat studies of NCI (Table 4) .
From these tables, liver cancer in mice exposed to toxaphene has highest slope factor. For conservative purpose, we should select the highest upper 95% CI which is 0.8557 (mg/kg/d) -1 (male mice cancer) as slope factor to use for calculation of carcinogenic risk in human population.
From the US Environmental Protection Agency's Integrated Risk Information System (IRIS), slope factor for toxaphene is 1.1 (mg/kg/d) -1 and weight of evidence is B2 which is probable human carcinogen, inadequate or no human data. The difference of slope factor between calculation and IRIS may be from differences in method and animal studies used to derive slope factor; however, in next step, the slope factor derived from calculation, 0.8557 (mg/kg/d) -1 , will be used.
Assumption for dose-response assessment 1. This assessment is only based on animal data so we assume that there is similar cancer effect in human as in animal study. 2. Assume that data from these studies fit in the linear regression model to derive slope factors. 3. Upper 95% CI of slope factor is chosen for conservative purpose. 4. Assume that the highest slope factor value is the most appropriate to use for risk characterization. III. Exposure Assessment Exposure data using for risk assessment From existing data of toxaphene levels in each media above, the exposure level selected for risk assessment is shown in Table 5 2) .
Calculation for estimating chemical intake The following equations for computing a lifetime average daily dose (LADD) for chronic exposure to chemicals are used: Estimated lifetime average daily dose for each exposure pathway is shown in Table 6 . Assumption for exposure assessment 1. Because of no current exposure data, the latest data in the past are used by assumption that the past level are similar to current level (not true because there is trend that level of toxaphene is reduced). 2. Level that were present came from positive sample data so the real levels were less than the value presented. 3. Assumption of ingestion and inhalation rates for calculation. 4. Assumption of body weight-use only male adult weight in calculation. 5. Assume that there are exposure to toxaphene by each pathway everyday. 6. Assume that the absorption of toxaphene into human body is perfect so the lifetime average daily dose is equal to the lifetime average daily exposure (LADD = LADE). In this assessment, SF = 0.8557 (mg/kg/d) -1 (from doseresponse assessment), and LADD from each exposure pathway (from exposure-assessment) are used to derive risk as result shown in Table 7 .
From Table 7 , cancer risk of toxaphene for average exposure is 7.42 × 10 -5 which means that a person would have a 7.4 in 100,000 chance of getting cancer from toxaphene. For highest exposure, cancer risk is 6.30 × 10 -3 -a person would have a six-in-a-thousand chance of getting cancer from toxaphene. Application of these risk estimates should be cautious because most exposure data used in assessment are from 1980s that were much higher from the current level. 
Consideration of site-specific human studies
There is no available health risk assessment for toxaphene to compare with risk assessment values in this paper.
Discussion
In conclusion, based on the animal studies for carcinogenicity of toxaphene, and exposure of adult general population to toxaphene from inhalation and ingestion pathways, the total cancer risk for toxaphene are 7.42 × 10 -5 and 6.30 × 10 -3 for average exposure and highest exposure, respectively. These cancer risk values are based on all assumptions and uncertainties shown above.
